Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RBOT.WS vs CDRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDRE Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

CDRE Overall Winner 6-Pillar Tally: RBOT.WS 0 – 6 CDRE Matrix Metrics: RBOT.WS 1 – 9 CDRE

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas CDRE carries 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. CDRE 39.6/100 SELL), CDRE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. N/A operating margin) and revenue trajectory (+30.2% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RBOT.WS vs CDRE
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
CDRE NYSE Head-to-Head Winner
Cadre Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$29.45
-3.63% 1D
Market Cap $1.3B
TTM Revenue $733M
Forward P/E 18.5x
Beta / 30D Vol 0.87β · 42% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 40.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.7 · SMA20: $31.80 · SMA50: $28.53

6-Pillar Scorecard Institutional Category Breakdown (RBOT.WS 0 – 6 CDRE)

Columns: Metric · RBOT.WS · CDRE
1. Valuation Multiples CDRE
Forward P/E N/M 18.5x
Trailing P/E N/M 33.6x
PEG Ratio N/M N/M
EV / Revenue N/M 2.2x
2. Growth & Scale CDRE
Revenue Growth (YoY) N/A +30.2%
Earnings Growth (YoY) N/A +37.5%
TTM Revenue (USD) N/A $733M
Market Cap N/A $1.3B
3. Profitability & Quality CDRE
Gross Margin N/A 42.8%
Operating Margin N/A 12.5%
Net Profit Margin N/A 5.6%
Return on Equity (ROE) N/A 11.6%
4. Balance Sheet & Cash Flow CDRE
Cash Generation (TTM) N/A $76M
Cash Flow Margin N/A 10.4%
Net Cash / Leverage N/A ROE $330M Net Debt (1.08x D/E)
Dividend Yield None (0.00%) 1.24%
5. Options & Positioning CDRE
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 47.3% (2nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat CDRE
OpEx & R&D Intensity N/A 30.3% of Rev ($222M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator Aerospace & Defense Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RBOT.WS (1) vs CDRE (9)
Institutional Metric RBOT.WS CDRE Criterion Row Edge
Market Capitalization
Scale
N/A $1.3B Larger Scale CDRE
Trailing P/E Ratio
Valuation
N/M 33.6x Lower Multiple CDRE
Forward P/E Ratio
Valuation
N/M 18.5x Lower Multiple CDRE
Revenue Growth (YoY)
Growth
N/A +30.2% Higher Growth CDRE
Operating Margin (TTM)
Profitability
N/A 12.5% Higher Margin CDRE
Net Profit Margin
Profitability
N/A 5.6% Higher Margin CDRE
Return on Equity (ROE)
Capital Efficiency
N/A 11.6% Higher ROE CDRE
52-Week Range Position
Momentum
0% ($0–$0) 22% ($24–$49) Stronger Trend CDRE
Beta / 30D Volatility
Risk Regime
N/A 0.87β · 42% Vol Lower Realized Risk CDRE
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 39.6 / 100 (SELL) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
N/A $733M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 42.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $76M ($330M Net Debt (1.08x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDRE +72.55 pp
RBOT.WS: -67.2% · CDRE: +5.35%
3M Horizon CDRE +72.55 pp
RBOT.WS: -67.2% · CDRE: +5.35%
6M Horizon CDRE +72.55 pp
RBOT.WS: -67.2% · CDRE: +5.35%
1Y Horizon CDRE +72.55 pp
RBOT.WS: -67.2% · CDRE: +5.35%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs CDRE. Trailing 12-month operating profitability (RBOT.WS N/A vs CDRE 12.5%) and valuation multiples (RBOT.WS N/M vs CDRE 18.5x Forward P/E) are benchmarked directly in Pillar 4 below.

RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CDRE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$733M
Gross Margin42.8%
Op. Margin12.5%
ROE / Fwd P/E11.6% · 18.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDRE SURGE
9d in phase · OBV DISTRIBUTION
Current IV 47.3%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact CDRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDRE Moat Profile Cyclical / Execution-Driven Positioning
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $1.3B market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment 30.3% of Rev ($222M)
90D Engineering Disclosures 0 Published

Investor FAQ RBOT.WS vs CDRE Key Questions & Quantitative Answers

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas CDRE carries 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. CDRE 39.6/100 SELL), CDRE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. N/A operating margin) and revenue trajectory (+30.2% vs. N/A YoY).

CDRE leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CDRE at +30.2% YoY revenue growth and +37.5% YoY earnings growth on $733M TTM revenue (42.8% gross margin, 12.5% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $733M for CDRE. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 30.3% of Rev ($222M) (0 disclosures) for CDRE.

CDRE screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CDRE trades at 18.5x Forward P/E, 33.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (10.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus CDRE (11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, CDRE carries 47.3% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.87β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.